Utilising benefit-risk assessments within clinical trials-a protocol for the BRAINS project.
Benefit-risk
Health technology assessment
Randomised controlled trials
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
19 Jan 2021
19 Jan 2021
Historique:
received:
09
03
2020
accepted:
05
01
2021
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Depending on the treatment to be investigated, a clinical trial could be designed to assess objectives of superiority, equivalence or non-inferiority. The design of the study is affected by many different elements including the control treatment, the primary outcome and associated relationships. In some studies, there could be more than one outcome of interest. In these situations, benefit-risk methodologies could be used to assess the outcomes simultaneously and consider the trade-off between the benefits against the risks of a treatment. Benefit-risk is used within the regulatory industry but seldom included within publicly funded clinical trials within the UK. This project aims to gain an expert consensus on how to select the appropriate trial design (e.g. superiority) and when to consider including benefit-risk methods. The project will consist of four work packages: 1. A web-based survey to elicit current experiences and opinions, 2. A rapid literature review to assess any current recommendations, 3. A two-day consensus workshop to gain agreement on the recommendations, and 4. Production of a guidance document. The aim of the project is to provide a guideline for clinical researchers, grant funding bodies and reviewers for grant bodies for how to select the most appropriate trial design and when it is appropriate to consider using benefit-risk methods. The focus of the guideline will be on publicly funded trials however, the vision is that the work will be applicable across research settings and we will connect with other organisations and committees as appropriate.
Sections du résumé
BACKGROUND
BACKGROUND
Depending on the treatment to be investigated, a clinical trial could be designed to assess objectives of superiority, equivalence or non-inferiority. The design of the study is affected by many different elements including the control treatment, the primary outcome and associated relationships. In some studies, there could be more than one outcome of interest. In these situations, benefit-risk methodologies could be used to assess the outcomes simultaneously and consider the trade-off between the benefits against the risks of a treatment. Benefit-risk is used within the regulatory industry but seldom included within publicly funded clinical trials within the UK. This project aims to gain an expert consensus on how to select the appropriate trial design (e.g. superiority) and when to consider including benefit-risk methods.
METHODS
METHODS
The project will consist of four work packages: 1. A web-based survey to elicit current experiences and opinions, 2. A rapid literature review to assess any current recommendations, 3. A two-day consensus workshop to gain agreement on the recommendations, and 4. Production of a guidance document.
DISCUSSION
CONCLUSIONS
The aim of the project is to provide a guideline for clinical researchers, grant funding bodies and reviewers for grant bodies for how to select the most appropriate trial design and when it is appropriate to consider using benefit-risk methods. The focus of the guideline will be on publicly funded trials however, the vision is that the work will be applicable across research settings and we will connect with other organisations and committees as appropriate.
Identifiants
pubmed: 33468202
doi: 10.1186/s13063-021-05022-0
pii: 10.1186/s13063-021-05022-0
pmc: PMC7814532
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
68Subventions
Organisme : Medical Research Council
ID : MC_PC_18018
Pays : United Kingdom
Références
Health Technol Assess. 1998;2(3):i-iv, 1-88
pubmed: 9561895
Am J Public Health. 1972 Mar;62(3):337-42
pubmed: 5011164
Int J Lang Commun Disord. 2006 Sep-Oct;41(5):567-82
pubmed: 17050471
Drug Discov Today Technol. 2011 Spring;8(1):e1-e42
pubmed: 24103837
Biomed Digit Libr. 2006 Jun 29;3:7
pubmed: 16805916
Syst Rev. 2016 Oct 11;5(1):172
pubmed: 27729071
Bull NYU Hosp Jt Dis. 2008;66(2):150-4
pubmed: 18537788
Pharmacoeconomics. 2010;28(10):855-65
pubmed: 20831293
Value Health. 2016 Sep - Oct;19(6):734-740
pubmed: 27712699
Clin Pharmacol Ther. 2007 Aug;82(2):123-7
pubmed: 17632534
BMC Med. 2018 Nov 16;16(1):210
pubmed: 30442137
Trials. 2011 May 03;12:106
pubmed: 21539749